Multiple copies of the oxytetracycline gene cluster in selected Streptomyces rimosus strains can provide significantly increased titers
Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commerc...
Saved in:
| Published in | Microbial cell factories Vol. 20; no. 1; pp. 47 - 19 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
17.02.2021
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commercial production. Although great efforts have been invested in strain selection methods, many of these technologies have not been improved in decades, which might pose a serious threat to the economic and industrial viability of such important bioprocesses.
In recent years, introduction of extra copies of an entire biosynthetic pathway that encodes a target product in a single microbial host has become a technically feasible approach. However, this often results in minor to moderate increases in target titers. Strain stability and process reproducibility are the other critical factors in the industrial setting. Industrial Streptomyces rimosus strains for production of oxytetracycline are one of the most economically efficient strains ever developed, and thus these represent a very good industrial case. To evaluate the applicability of amplification of an entire gene cluster in a single host strain, we developed and evaluated various gene tools to introduce multiple copies of the entire oxytetracycline gene cluster into three different Streptomyces rimosus strains: wild-type, and medium and high oxytetracycline-producing strains. We evaluated the production levels of these engineered S. rimosus strains with extra copies of the oxytetracycline gene cluster and their stability, and the oxytetracycline gene cluster expression profiles; we also identified the chromosomal integration sites.
This study shows that stable and reproducible increases in target secondary metabolite titers can be achieved in wild-type and in high oxytetracycline-producing strains, which always reflects the metabolic background of each independent S. rimosus strain. Although this approach is technically very demanding and requires systematic effort, when combined with modern strain selection methods, it might constitute a very valuable approach in industrial process development. |
|---|---|
| AbstractList | Background Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commercial production. Although great efforts have been invested in strain selection methods, many of these technologies have not been improved in decades, which might pose a serious threat to the economic and industrial viability of such important bioprocesses. Results In recent years, introduction of extra copies of an entire biosynthetic pathway that encodes a target product in a single microbial host has become a technically feasible approach. However, this often results in minor to moderate increases in target titers. Strain stability and process reproducibility are the other critical factors in the industrial setting. Industrial Streptomyces rimosus strains for production of oxytetracycline are one of the most economically efficient strains ever developed, and thus these represent a very good industrial case. To evaluate the applicability of amplification of an entire gene cluster in a single host strain, we developed and evaluated various gene tools to introduce multiple copies of the entire oxytetracycline gene cluster into three different Streptomyces rimosus strains: wild-type, and medium and high oxytetracycline-producing strains. We evaluated the production levels of these engineered S. rimosus strains with extra copies of the oxytetracycline gene cluster and their stability, and the oxytetracycline gene cluster expression profiles; we also identified the chromosomal integration sites. Conclusions This study shows that stable and reproducible increases in target secondary metabolite titers can be achieved in wild-type and in high oxytetracycline-producing strains, which always reflects the metabolic background of each independent S. rimosus strain. Although this approach is technically very demanding and requires systematic effort, when combined with modern strain selection methods, it might constitute a very valuable approach in industrial process development. Keywords: Streptomyces rimosus, Oxytetracycline, ΦC31, Biosynthesis, Biosynthetic gene cluster Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commercial production. Although great efforts have been invested in strain selection methods, many of these technologies have not been improved in decades, which might pose a serious threat to the economic and industrial viability of such important bioprocesses. In recent years, introduction of extra copies of an entire biosynthetic pathway that encodes a target product in a single microbial host has become a technically feasible approach. However, this often results in minor to moderate increases in target titers. Strain stability and process reproducibility are the other critical factors in the industrial setting. Industrial Streptomyces rimosus strains for production of oxytetracycline are one of the most economically efficient strains ever developed, and thus these represent a very good industrial case. To evaluate the applicability of amplification of an entire gene cluster in a single host strain, we developed and evaluated various gene tools to introduce multiple copies of the entire oxytetracycline gene cluster into three different Streptomyces rimosus strains: wild-type, and medium and high oxytetracycline-producing strains. We evaluated the production levels of these engineered S. rimosus strains with extra copies of the oxytetracycline gene cluster and their stability, and the oxytetracycline gene cluster expression profiles; we also identified the chromosomal integration sites. This study shows that stable and reproducible increases in target secondary metabolite titers can be achieved in wild-type and in high oxytetracycline-producing strains, which always reflects the metabolic background of each independent S. rimosus strain. Although this approach is technically very demanding and requires systematic effort, when combined with modern strain selection methods, it might constitute a very valuable approach in industrial process development. Abstract Background Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commercial production. Although great efforts have been invested in strain selection methods, many of these technologies have not been improved in decades, which might pose a serious threat to the economic and industrial viability of such important bioprocesses. Results In recent years, introduction of extra copies of an entire biosynthetic pathway that encodes a target product in a single microbial host has become a technically feasible approach. However, this often results in minor to moderate increases in target titers. Strain stability and process reproducibility are the other critical factors in the industrial setting. Industrial Streptomyces rimosus strains for production of oxytetracycline are one of the most economically efficient strains ever developed, and thus these represent a very good industrial case. To evaluate the applicability of amplification of an entire gene cluster in a single host strain, we developed and evaluated various gene tools to introduce multiple copies of the entire oxytetracycline gene cluster into three different Streptomyces rimosus strains: wild-type, and medium and high oxytetracycline-producing strains. We evaluated the production levels of these engineered S. rimosus strains with extra copies of the oxytetracycline gene cluster and their stability, and the oxytetracycline gene cluster expression profiles; we also identified the chromosomal integration sites. Conclusions This study shows that stable and reproducible increases in target secondary metabolite titers can be achieved in wild-type and in high oxytetracycline-producing strains, which always reflects the metabolic background of each independent S. rimosus strain. Although this approach is technically very demanding and requires systematic effort, when combined with modern strain selection methods, it might constitute a very valuable approach in industrial process development. Background Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commercial production. Although great efforts have been invested in strain selection methods, many of these technologies have not been improved in decades, which might pose a serious threat to the economic and industrial viability of such important bioprocesses. Results In recent years, introduction of extra copies of an entire biosynthetic pathway that encodes a target product in a single microbial host has become a technically feasible approach. However, this often results in minor to moderate increases in target titers. Strain stability and process reproducibility are the other critical factors in the industrial setting. Industrial Streptomyces rimosus strains for production of oxytetracycline are one of the most economically efficient strains ever developed, and thus these represent a very good industrial case. To evaluate the applicability of amplification of an entire gene cluster in a single host strain, we developed and evaluated various gene tools to introduce multiple copies of the entire oxytetracycline gene cluster into three different Streptomyces rimosus strains: wild-type, and medium and high oxytetracycline-producing strains. We evaluated the production levels of these engineered S. rimosus strains with extra copies of the oxytetracycline gene cluster and their stability, and the oxytetracycline gene cluster expression profiles; we also identified the chromosomal integration sites. Conclusions This study shows that stable and reproducible increases in target secondary metabolite titers can be achieved in wild-type and in high oxytetracycline-producing strains, which always reflects the metabolic background of each independent S. rimosus strain. Although this approach is technically very demanding and requires systematic effort, when combined with modern strain selection methods, it might constitute a very valuable approach in industrial process development. Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commercial production. Although great efforts have been invested in strain selection methods, many of these technologies have not been improved in decades, which might pose a serious threat to the economic and industrial viability of such important bioprocesses.BACKGROUNDNatural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commercial production. Although great efforts have been invested in strain selection methods, many of these technologies have not been improved in decades, which might pose a serious threat to the economic and industrial viability of such important bioprocesses.In recent years, introduction of extra copies of an entire biosynthetic pathway that encodes a target product in a single microbial host has become a technically feasible approach. However, this often results in minor to moderate increases in target titers. Strain stability and process reproducibility are the other critical factors in the industrial setting. Industrial Streptomyces rimosus strains for production of oxytetracycline are one of the most economically efficient strains ever developed, and thus these represent a very good industrial case. To evaluate the applicability of amplification of an entire gene cluster in a single host strain, we developed and evaluated various gene tools to introduce multiple copies of the entire oxytetracycline gene cluster into three different Streptomyces rimosus strains: wild-type, and medium and high oxytetracycline-producing strains. We evaluated the production levels of these engineered S. rimosus strains with extra copies of the oxytetracycline gene cluster and their stability, and the oxytetracycline gene cluster expression profiles; we also identified the chromosomal integration sites.RESULTSIn recent years, introduction of extra copies of an entire biosynthetic pathway that encodes a target product in a single microbial host has become a technically feasible approach. However, this often results in minor to moderate increases in target titers. Strain stability and process reproducibility are the other critical factors in the industrial setting. Industrial Streptomyces rimosus strains for production of oxytetracycline are one of the most economically efficient strains ever developed, and thus these represent a very good industrial case. To evaluate the applicability of amplification of an entire gene cluster in a single host strain, we developed and evaluated various gene tools to introduce multiple copies of the entire oxytetracycline gene cluster into three different Streptomyces rimosus strains: wild-type, and medium and high oxytetracycline-producing strains. We evaluated the production levels of these engineered S. rimosus strains with extra copies of the oxytetracycline gene cluster and their stability, and the oxytetracycline gene cluster expression profiles; we also identified the chromosomal integration sites.This study shows that stable and reproducible increases in target secondary metabolite titers can be achieved in wild-type and in high oxytetracycline-producing strains, which always reflects the metabolic background of each independent S. rimosus strain. Although this approach is technically very demanding and requires systematic effort, when combined with modern strain selection methods, it might constitute a very valuable approach in industrial process development.CONCLUSIONSThis study shows that stable and reproducible increases in target secondary metabolite titers can be achieved in wild-type and in high oxytetracycline-producing strains, which always reflects the metabolic background of each independent S. rimosus strain. Although this approach is technically very demanding and requires systematic effort, when combined with modern strain selection methods, it might constitute a very valuable approach in industrial process development. Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commercial production. Although great efforts have been invested in strain selection methods, many of these technologies have not been improved in decades, which might pose a serious threat to the economic and industrial viability of such important bioprocesses. In recent years, introduction of extra copies of an entire biosynthetic pathway that encodes a target product in a single microbial host has become a technically feasible approach. However, this often results in minor to moderate increases in target titers. Strain stability and process reproducibility are the other critical factors in the industrial setting. Industrial Streptomyces rimosus strains for production of oxytetracycline are one of the most economically efficient strains ever developed, and thus these represent a very good industrial case. To evaluate the applicability of amplification of an entire gene cluster in a single host strain, we developed and evaluated various gene tools to introduce multiple copies of the entire oxytetracycline gene cluster into three different Streptomyces rimosus strains: wild-type, and medium and high oxytetracycline-producing strains. We evaluated the production levels of these engineered S. rimosus strains with extra copies of the oxytetracycline gene cluster and their stability, and the oxytetracycline gene cluster expression profiles; we also identified the chromosomal integration sites. This study shows that stable and reproducible increases in target secondary metabolite titers can be achieved in wild-type and in high oxytetracycline-producing strains, which always reflects the metabolic background of each independent S. rimosus strain. Although this approach is technically very demanding and requires systematic effort, when combined with modern strain selection methods, it might constitute a very valuable approach in industrial process development. |
| ArticleNumber | 47 |
| Audience | Academic |
| Author | Carrillo Rincón, Andrés Felipe Baebler, Špela Avbelj, Martina Šala, Martin Goranovič, Dušan Magdevska, Vasilka Pikl, Špela Slemc, Lucija Luzhetskyy, Andriy Gjuračić, Krešimir Sucipto, Hilda Stare, Katja Guo, Meijin Petković, Hrvoje |
| Author_xml | – sequence: 1 givenname: Špela surname: Pikl fullname: Pikl, Špela – sequence: 2 givenname: Andrés Felipe surname: Carrillo Rincón fullname: Carrillo Rincón, Andrés Felipe – sequence: 3 givenname: Lucija surname: Slemc fullname: Slemc, Lucija – sequence: 4 givenname: Dušan surname: Goranovič fullname: Goranovič, Dušan – sequence: 5 givenname: Martina surname: Avbelj fullname: Avbelj, Martina – sequence: 6 givenname: Krešimir surname: Gjuračić fullname: Gjuračić, Krešimir – sequence: 7 givenname: Hilda surname: Sucipto fullname: Sucipto, Hilda – sequence: 8 givenname: Katja surname: Stare fullname: Stare, Katja – sequence: 9 givenname: Špela surname: Baebler fullname: Baebler, Špela – sequence: 10 givenname: Martin surname: Šala fullname: Šala, Martin – sequence: 11 givenname: Meijin surname: Guo fullname: Guo, Meijin – sequence: 12 givenname: Andriy surname: Luzhetskyy fullname: Luzhetskyy, Andriy – sequence: 13 givenname: Hrvoje surname: Petković fullname: Petković, Hrvoje – sequence: 14 givenname: Vasilka surname: Magdevska fullname: Magdevska, Vasilka |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33596911$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstq3DAYhU1JaS7tC3RRBN20C6e6WLdNIYReBlIKTbsWivzb0eCxXEkOmSfoa1czk7SZUIpBFr_P-ZCOz3F1MIYRquolwaeEKPEuEapZU2NKakw4pTV_Uh2RRvKaKq4PHuwPq-OUlhgTqSR7Vh0yxrXQhBxVv77MQ_bTAMiFyUNCoUP5GlC4XWfI0bq1G_wIqIeyuGFOGSLyI0owgMvQosscYcphtXbFHP0qpDmhVJx-TMjZEU0x3PgWUPL96DtfRnlYF4SLYFMBZF-Q6Xn1tLNDghd375Pqx8cP388_1xdfPy3Ozy5qx7XMdWMlpxZjyTCAtkKAII0SjMoWW9bR1jWtI41zWkiupGsVYMew0ldMMK0cO6kWO24b7NJM5cA2rk2w3mwHIfbGxuzdAKalgjvSUanaEqTQqpVUWKclwYIKKQvr_Y41zVcraB2M5drDHnT_y-ivTR9ujFQaC6IL4M0dIIafM6RsVj45GAY7QpiToY0mWGLRqCJ9_Ui6DHMcS1RbVUOYpvqvqrflAn7swuYXbqDmTHAmCOWEFdXpP1TlaWHlXelY58t8z_B2z1A0GW5zb-eUzOLy27721cNQ_qRxX7kiUDuBiyGlCJ1xPtvswyYjPxiCzabdZtduU9pttu02vFjpI-s9_T-m3xe5_Ag |
| CitedBy_id | crossref_primary_10_1186_s12934_023_02215_x crossref_primary_10_1186_s40694_023_00152_3 crossref_primary_10_1128_msystems_00250_24 crossref_primary_10_3390_ijms25063127 crossref_primary_10_1016_j_mimet_2022_106545 |
| Cites_doi | 10.1007/s00253-015-7256-z 10.1186/1475-2859-12-126 10.1111/j.1574-6968.1999.tb13576.x 10.1038/srep08740 10.1007/s00253-014-5523-z 10.1007/s10295-016-1842-7 10.1038/nprot.2008.5 10.1016/j.jbiotec.2016.05.038 10.1099/00221287-143-5-1493 10.1186/1471-2180-12-238 10.1016/j.jmb.2003.09.082 10.1186/s12934-019-1181-2 10.1038/nrd4510 10.1016/j.ymben.2017.01.004 10.1007/978-1-59745-494-0_8 10.1007/s10295-015-1723-5 10.1038/ja.2017.142 10.1128/AEM.59.7.2220-2228.1993 10.1007/BF00339722 10.1186/s12934-016-0496-5 10.1186/s12859-017-1688-7 10.1186/1472-6750-12-52 10.1016/0022-2836(91)90584-S 10.1093/abbs/gmx110 10.1007/BF01027134 10.1073/pnas.1108124108 10.1128/JB.184.20.5746-5752.2002 10.1016/0378-1119(90)90467-6 10.1128/JB.185.17.5320-5323.2003 10.1016/S0065-2164(04)54004-2 10.1016/j.fgb.2006.03.001 10.1093/nar/19.19.5187 10.1016/j.ymben.2018.12.001 10.1128/JB.181.10.3025-3032.1999 10.1111/j.1472-765X.2010.02835.x 10.1111/j.1574-6968.1997.tb13882.x 10.1007/s10529-007-9586-0 10.1128/MMBR.00019-15 10.1007/s00253-019-09970-1 10.1038/ja.2017.30 10.1021/ja403516u 10.1128/AEM.00434-11 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
| Copyright_xml | – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
| DBID | AAYXX CITATION NPM ISR 3V. 7QL 7T7 7U9 7X7 7XB 88E 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12934-021-01522-5 |
| DatabaseName | CrossRef PubMed Gale in Context: Science ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 1475-2859 |
| EndPage | 19 |
| ExternalDocumentID | oai_doaj_org_article_d265c1f278d147698d726ac971062677 PMC7890619 A653612513 33596911 10_1186_s12934_021_01522_5 |
| Genre | Journal Article |
| GeographicLocations | Slovenia |
| GeographicLocations_xml | – name: Slovenia |
| GrantInformation_xml | – fundername: Javna Agencija za Raziskovalno Dejavnost RS grantid: Programska skupina P4-0116 – fundername: Javna Agencija za Raziskovalno Dejavnost RS grantid: P4-0116 – fundername: ERA-Co Biotech, NISSION grantid: 031B0611A – fundername: Ministrstvo za visoko šolstvo, znanost in tehnologijo grantid: ERACoBiotec No. C3330-18-2520013 – fundername: Javna Agencija za Raziskovalno Dejavnost RS grantid: P4-0165 – fundername: ; grantid: P4-0165 – fundername: ; grantid: P4-0116 – fundername: ; grantid: 031B0611A – fundername: ; grantid: Programska skupina P4-0116 – fundername: ; grantid: ERACoBiotec No. C3330-18-2520013 |
| GroupedDBID | --- 0R~ 123 29M 2WC 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ A8Z AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IGS IHR INH INR ISR ITC KQ8 LK8 M1P M48 M7P MM. M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SCM SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M -58 -5G -A0 -BR 3V. ACRMQ ADINQ C24 FRP NPM PMFND 7QL 7T7 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c597t-4a752a00730ee9a66e61486327d0a3f2dc4dc14cc967587cd8e0c3089b36398c3 |
| IEDL.DBID | M48 |
| ISSN | 1475-2859 |
| IngestDate | Wed Aug 27 01:20:40 EDT 2025 Thu Aug 21 13:55:01 EDT 2025 Fri Jul 11 03:38:06 EDT 2025 Fri Jul 25 10:59:09 EDT 2025 Tue Jun 17 21:29:14 EDT 2025 Tue Jun 10 20:07:34 EDT 2025 Fri Jun 27 04:19:23 EDT 2025 Wed Feb 19 02:29:33 EST 2025 Thu Apr 24 23:09:49 EDT 2025 Tue Jul 01 02:30:24 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Oxytetracycline Streptomyces rimosus ΦC31 Biosynthesis Biosynthetic gene cluster |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c597t-4a752a00730ee9a66e61486327d0a3f2dc4dc14cc967587cd8e0c3089b36398c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2491413929?pq-origsite=%requestingapplication% |
| PMID | 33596911 |
| PQID | 2491413929 |
| PQPubID | 42699 |
| PageCount | 19 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d265c1f278d147698d726ac971062677 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7890619 proquest_miscellaneous_2491070648 proquest_journals_2491413929 gale_infotracmisc_A653612513 gale_infotracacademiconefile_A653612513 gale_incontextgauss_ISR_A653612513 pubmed_primary_33596911 crossref_citationtrail_10_1186_s12934_021_01522_5 crossref_primary_10_1186_s12934_021_01522_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-02-17 |
| PublicationDateYYYYMMDD | 2021-02-17 |
| PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Microbial cell factories |
| PublicationTitleAlternate | Microb Cell Fact |
| PublicationYear | 2021 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | P Combes (1522_CR25) 2002; 184 EA Barka (1522_CR1) 2016; 80 T Smokvina (1522_CR31) 1990; 94 AC Groth (1522_CR27) 2004; 335 AL Harvey (1522_CR2) 2015; 14 K Karničar (1522_CR8) 2016; 15 E Martens (1522_CR4) 2017; 70 IBM Corp (1522_CR21) 2017 D Du (1522_CR33) 2015; 5 JL Revuelta (1522_CR12) 2017; 44 MK Kim (1522_CR30) 2008; 30 1522_CR9 1522_CR7 U Lešnik (1522_CR35) 2009; 47 S Kuhstoss (1522_CR24) 1991; 222 X Wang (1522_CR18) 2019; 103 J Ishikawa (1522_CR23) 1999; 174 1522_CR38 MJ Butler (1522_CR46) 1989; 215 L Li (1522_CR16) 2017; 40 AL Demain (1522_CR5) 2008; 65 S Sanchez (1522_CR3) 2017; 71 T Murakami (1522_CR11) 2011; 108 L Yu (1522_CR36) 2012; 12 N Wu (1522_CR41) 2017; 49 R MoraLugo (1522_CR10) 2019; 18 F Flett (1522_CR39) 1997; 155 KJ McDowall (1522_CR20) 1999; 181 K Pandza (1522_CR34) 1997; 143 B Kirm (1522_CR47) 2013; 12 SA Hadj (1522_CR6) 1988; 10 N Kouprina (1522_CR19) 2008; 3 MA Gregory (1522_CR32) 2003; 185 P Wang (1522_CR37) 2013; 135 F Fierro (1522_CR13) 2006; 43 S Phornphisutthimas (1522_CR28) 2010; 50 L Katz (1522_CR14) 2016; 43 1522_CR45 1522_CR22 L Li (1522_CR17) 2019; 52 1522_CR42 B Gust (1522_CR44) 2004; 54 N Manderscheid (1522_CR15) 2016; 232 H Rausch (1522_CR26) 1991; 19 M Myronovskyi (1522_CR43) 2014; 98 B Gravius (1522_CR29) 1993; 59 Š Baebler (1522_CR48) 2017; 18 1522_CR40 |
| References_xml | – ident: 1522_CR9 doi: 10.1007/s00253-015-7256-z – volume: 12 start-page: 126 issue: 1 year: 2013 ident: 1522_CR47 publication-title: Microb Cell Fact doi: 10.1186/1475-2859-12-126 – ident: 1522_CR40 – ident: 1522_CR42 – volume: 174 start-page: 251 year: 1999 ident: 1522_CR23 publication-title: FEMS Microbiol Lett doi: 10.1111/j.1574-6968.1999.tb13576.x – volume: 5 start-page: 8740 year: 2015 ident: 1522_CR33 publication-title: Sci Rep doi: 10.1038/srep08740 – volume: 98 start-page: 4557 issue: 10 year: 2014 ident: 1522_CR43 publication-title: Appl Microbiol Biotechnol doi: 10.1007/s00253-014-5523-z – volume: 44 start-page: 659 issue: 4–5 year: 2017 ident: 1522_CR12 publication-title: J Ind Microbiol Biotechnol doi: 10.1007/s10295-016-1842-7 – volume: 3 start-page: 371 issue: 3 year: 2008 ident: 1522_CR19 publication-title: Nat Protoc doi: 10.1038/nprot.2008.5 – volume: 232 start-page: 110 year: 2016 ident: 1522_CR15 publication-title: J Biotechnol doi: 10.1016/j.jbiotec.2016.05.038 – volume: 143 start-page: 1493 issue: 5 year: 1997 ident: 1522_CR34 publication-title: Microbiology doi: 10.1099/00221287-143-5-1493 – volume: 47 start-page: 323 issue: 3 year: 2009 ident: 1522_CR35 publication-title: Food Technol Biotechnol – ident: 1522_CR7 doi: 10.1186/1471-2180-12-238 – volume: 335 start-page: 667 year: 2004 ident: 1522_CR27 publication-title: J Mol Biol doi: 10.1016/j.jmb.2003.09.082 – volume: 18 start-page: 146 issue: 1 year: 2019 ident: 1522_CR10 publication-title: Microb Cell Fact doi: 10.1186/s12934-019-1181-2 – volume: 14 start-page: 111 issue: 2 year: 2015 ident: 1522_CR2 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd4510 – volume: 40 start-page: 80 year: 2017 ident: 1522_CR16 publication-title: Metab Eng doi: 10.1016/j.ymben.2017.01.004 – volume-title: IBM SPSS Statistics for Windows [Internet] year: 2017 ident: 1522_CR21 – volume: 65 start-page: 251,253 year: 2008 ident: 1522_CR5 publication-title: Prog drug Res Fortschritte der Arzneimittelforschung Prog des Rech Pharm – ident: 1522_CR22 doi: 10.1007/978-1-59745-494-0_8 – volume: 43 start-page: 155 issue: 2–3 year: 2016 ident: 1522_CR14 publication-title: J Ind Microbiol Biotechnol doi: 10.1007/s10295-015-1723-5 – volume: 71 start-page: 26 year: 2017 ident: 1522_CR3 publication-title: J Antibiot doi: 10.1038/ja.2017.142 – volume: 59 start-page: 2220 issue: 7 year: 1993 ident: 1522_CR29 publication-title: Appl Environ Microbiol doi: 10.1128/AEM.59.7.2220-2228.1993 – volume: 215 start-page: 231 issue: 2 year: 1989 ident: 1522_CR46 publication-title: Mol Gen Genet doi: 10.1007/BF00339722 – volume: 15 start-page: 93 year: 2016 ident: 1522_CR8 publication-title: Microb Cell Fact doi: 10.1186/s12934-016-0496-5 – volume: 18 start-page: 276 issue: 1 year: 2017 ident: 1522_CR48 publication-title: BMC Bioinformatics doi: 10.1186/s12859-017-1688-7 – volume: 12 start-page: 1 issue: 1 year: 2012 ident: 1522_CR36 publication-title: BMC Biotechnol doi: 10.1186/1472-6750-12-52 – volume: 222 start-page: 897 issue: 4 year: 1991 ident: 1522_CR24 publication-title: J Mol Biol doi: 10.1016/0022-2836(91)90584-S – volume: 49 start-page: 1129 issue: 12 year: 2017 ident: 1522_CR41 publication-title: Acta Biochim Biophys Sin (Shanghai) doi: 10.1093/abbs/gmx110 – volume: 10 start-page: 583 issue: 8 year: 1988 ident: 1522_CR6 publication-title: Biotechnol Lett doi: 10.1007/BF01027134 – volume: 108 start-page: 16020 issue: 38 year: 2011 ident: 1522_CR11 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1108124108 – volume: 184 start-page: 5746 issue: 20 year: 2002 ident: 1522_CR25 publication-title: J Bacteriol doi: 10.1128/JB.184.20.5746-5752.2002 – volume: 94 start-page: 53 issue: 1 year: 1990 ident: 1522_CR31 publication-title: Gene doi: 10.1016/0378-1119(90)90467-6 – volume: 185 start-page: 5320 issue: 17 year: 2003 ident: 1522_CR32 publication-title: J Bacteriol doi: 10.1128/JB.185.17.5320-5323.2003 – volume: 54 start-page: 107 year: 2004 ident: 1522_CR44 publication-title: Adv Appl Microbiol doi: 10.1016/S0065-2164(04)54004-2 – volume: 43 start-page: 618 issue: 9 year: 2006 ident: 1522_CR13 publication-title: Fungal Genet Biol. doi: 10.1016/j.fgb.2006.03.001 – volume: 19 start-page: 5187 issue: 19 year: 1991 ident: 1522_CR26 publication-title: Nucleic Acids Res doi: 10.1093/nar/19.19.5187 – volume: 52 start-page: 153 year: 2019 ident: 1522_CR17 publication-title: Metab Eng doi: 10.1016/j.ymben.2018.12.001 – volume: 181 start-page: 3025 issue: 10 year: 1999 ident: 1522_CR20 publication-title: J Bacteriol doi: 10.1128/JB.181.10.3025-3032.1999 – volume: 50 start-page: 530 issue: 5 year: 2010 ident: 1522_CR28 publication-title: Lett Appl Microbiol doi: 10.1111/j.1472-765X.2010.02835.x – volume: 155 start-page: 223 issue: 2 year: 1997 ident: 1522_CR39 publication-title: FEMS Microbiol Lett doi: 10.1111/j.1574-6968.1997.tb13882.x – volume: 30 start-page: 695 issue: 4 year: 2008 ident: 1522_CR30 publication-title: Biotechnol Lett doi: 10.1007/s10529-007-9586-0 – volume: 80 start-page: 1 issue: 1 year: 2016 ident: 1522_CR1 publication-title: Microbiol Mol Biol Rev doi: 10.1128/MMBR.00019-15 – volume: 103 start-page: 6645 issue: 16 year: 2019 ident: 1522_CR18 publication-title: Appl Microbiol Biotechnol doi: 10.1007/s00253-019-09970-1 – volume: 70 start-page: 520 issue: 5 year: 2017 ident: 1522_CR4 publication-title: J Antibiot doi: 10.1038/ja.2017.30 – ident: 1522_CR38 – volume: 135 start-page: 7138 issue: 19 year: 2013 ident: 1522_CR37 publication-title: J Am Chem Soc doi: 10.1021/ja403516u – ident: 1522_CR45 doi: 10.1128/AEM.00434-11 |
| SSID | ssj0017873 |
| Score | 2.3127282 |
| Snippet | Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural... Background Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with... Abstract Background Natural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 47 |
| SubjectTerms | Bioactive compounds Biological activity Biosynthesis Biosynthetic gene cluster Chromosomes Cloning Deoxyribonucleic acid DNA Engineering Enzymes Gene expression Genetic aspects Industrial microorganisms Metabolic engineering Metabolism Metabolites Microbiological research Microbiological synthesis Microorganisms Natural products Oxytetracycline Physiological aspects Production processes Reproducibility Stability Streptomyces Streptomyces rimosus Yeast ΦC31 |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pi9UwEA6yJz2Iv62uEkXwIGXbJk3S4youq7Ae1IW9hTRJdeHZPjYt7PsL9t92Js17vCLoxWszDe3MJPMNmflCyJuGiZYp43LwXUhQGtHmquYy565VtfEQZCPP9tkXcXrOP1_UF3tXfWFN2EwPPCvuyFWitmVXSeVKLkWjnKyEsQ1ERsDiMvaRQ8zbJlPp_ADckG1bZJQ4ChjVeI7lCBD-MP1ahKHI1v_nnrwXlJYFk3sR6OQeuZugIz2eP_k-ueX7B-TOHqHgQ3JzluoDqR3WkAPToaOA8OhwvRk9zGk32AnpKXgNiKwmZEmglz0N8TYc7ygeUq_H4dcGtg96BXYMU6Ah3iMRKFiBps49inUfWGUEhlltYAoEnwEmiDTN4RE5P_n4_cNpnq5ayC1kFGPOjawrg8d2hfeNEcIjQahglXSFYV3lLHe25NY2mGBI65QvLCtU0zKAOMqyx-SgH3r_lFDFuqaobOE63gFa8AamYIVVddeKUhUiI-VW89omHnL8jZWO-YgSeraWBmvpaC1dZ-Td7p31zMLxV-n3aNCdJDJoxwfgVzr5lf6XX2XkNbqDRo6MHotwfpgpBP3p21d9LGoWgSHLyNsk1A1oRJN6GkATSKu1kDxcSMIitsvhrdfptIkEDZlxCRgDAGxGXu2G8U0sjOv9MM0ysGsLrjLyZHbS3X8zVjcCgllG5MJ9F4pZjvSXPyPFOLZHQ2r97H9o8jm5XcWVV-WlPCQH49XkXwCSG9uXcdH-BoauQ3E priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELWgXOCA-CZQkEFIHFDUJE5s54QKoipI5QBU2pvl2E5baUmWdSKxv4C_zYzjXTZC6nU9sTae8cy8eOaZkDc14w2T2qZguwBQat6ksipFWtpGVtpBkA0822df-el5-WVRLeIHNx_LKrc-MThq2xv8Rn4EMCEHhwvR_P3qV4q3RuHparxC4ya5hdRlaNVisQNcORgj2zbKSH7kMbaVKRYlQBBEEDYLRoGz_3_PvBea5mWTe3Ho5B65GxNIejxp_D654boH5M4ereBD8ucsVglS068ACdO-pZDn0f73ZnAwp9lgP6SjYDsgshyRK4FeddSHO3GcpXhUvRr6nxtwInQN2vSjpz7cJuEp6ILG_j2K1R9YawTqWW5gCkxBPUwQyJr9I3J-8unHx9M0XriQGsAVQ1pqURUaD-8y52rNuUOaUM4KYTPN2sKa0pq8NKZGmCGMlS4zLJN1wyDRkYY9Jgdd37mnhErW1llhMtuWLeQMTsMULDOyahuey4wnJN-uvDKRjRxfY6kCKpFcTdpSoC0VtKWqhLzbPbOauDiulf6ACt1JIo92-KFfX6i4LZUteGXythDS5qXgtbSi4NrUkHcB0hMiIa_RHBQyZXRYinOhR-_V5-_f1DGvWEgPWULeRqG2RyXq2NkAK4HkWjPJw5kkbGUzH95anYquxKt_hp-QV7thfBLL4zrXj5MM-G5eyoQ8mYx0996MVTWHkJYQMTPf2cLMR7qry0A0jk3SALCfXf-3npPbRdhTRZqLQ3IwrEf3AjK1oXkZtuNfBQ48lw priority: 102 providerName: ProQuest |
| Title | Multiple copies of the oxytetracycline gene cluster in selected Streptomyces rimosus strains can provide significantly increased titers |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33596911 https://www.proquest.com/docview/2491413929 https://www.proquest.com/docview/2491070648 https://pubmed.ncbi.nlm.nih.gov/PMC7890619 https://doaj.org/article/d265c1f278d147698d726ac971062677 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED_tQ0LjAfFNYFQGIfGAAkmc2M4DQhvaNJA6oUGlvlmJ44xJJSlNKy1_Af82d25SGjF4rc8nxXfnu6vvfgfwKuUi5yorfNRdTFBSkfsqiaUfF7lKMotO1uFsj8_F2ST-PE2mO9CPO-oOsLkxtaN5UpPF7O31z_YDGvx7Z_BKvGvIZ8U-FRugc6Pkahf20TNJmmgwjv-8KqBy8r5x5sZ9B3CL8yQVaRgO_JSD8__70t7yWsOKyi0XdXoX7nSxJTtaK8M92LHVfbi9hTj4AH6NuwJCZuo5JsmsLhmGgKy-bpcWeZqWWiUtQ7VCktmKYBTYVcUaNy7HFoxesefL-keL9wtboKCbVcMaN2iiYSgm1rX2MSoMoTIklNysRRYUnTbIwOE4Nw9hcnry7eOZ381i8A2mHEs_zmQSZfSuF1ibZkJYQhAVPJJFkPEyKkxcmDA2JqUMRJpC2cDwQKU5xxhIGf4I9qq6sk-AKV6mQWSCooxLDCdshix4YFRS5iJUgfAg7E9emw6onD5jpl3CooReC06j4LQTnE48eLPZM1_DdPyX-pgEuqEkiG33Q7241J3F6iISiQnLSKoijKVIVSEjkZkUQzJMAqX04CWpgyYQjYqqdC6zVdPoT18v9JFIuIscuQevO6KyJiFmXdMDngThbg0oDweUaOVmuNxrne6NRGPqHGIQghGuBy82y7STKucqW6_WNHiti1h58HitpJvv7nXdAzlQ38HBDFeqq-8Og5z6pzH3fvpPns_gIHKWFfmhPIS95WJln2P8tsxHsCuncgT7xyfnXy5G7l-QkTPU33t9QwU |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKOQAHxJtAAYNAHFDUJE5s54BQeVS7tNsDtNLe3MR2SqUlWda7gv0F_Bt-IzNOdtkIqbde15PRxjOebyaeByEvc8ZLJgsTgu5CgJLzMpRZKsLUlDIrLICs77M9OuKDk_TzOBtvkT-rWhhMq1zZRG-oTaPxG_kuhAkxGFxA83fTHyFOjcLb1dUIjVYtDuzyJ4Rs7u3wI8j3VZLsfzr-MAi7qQKhBud5HqaFyJICb6gia_OCc4u9MDlLhIkKViVGp0bHqdY5-tJCG2kjzSKZlwzQXGoGfK-QqwC8EQZ7YrwO8GJQfrYqzJF81yGWpiEmQQDoYtDXAz8_I-B_JNiAwn6a5gbu7d8iNzuHle61GnabbNn6Drmx0cbwLvk96rISqW6mEHnTpqLgV9Lm13JugadeYv2lpaCrQDJZYG8Gel5T52fwWEPxanw6b74vwWjRGWiPWzjq_PQKR0H2tKsXpJhtgrlNoA6TJbBAl9cBA98c2t0jJ5ciivtku25q-5BQyao8SnRkqrQCH8UWwIJFWmZVyWMZ8YDEq51Xuut-jq8xUT4Kkly10lIgLeWlpbKAvFk_M217f1xI_R4FuqbEvt3-h2Z2pjozoEzCMx1XiZAmTgXPpREJL3QOfh5ElkIE5AWqg8LOHDWm_pwVC-fU8OsXtccz5t1RFpDXHVHVoBCLrpICdgKbefUod3qUYDp0f3mldaozXU79O2gBeb5exicxHa-2zaKlAazgqQzIg1ZJ1-_NWJZzgNCAiJ769jamv1Kff_ONzbEoGwL6Rxf_rWfk2uB4dKgOh0cHj8n1xJ-vJIzFDtmezxb2CXiJ8_KpP5qUnF62LfgLA914Ng |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multiple+copies+of+the+oxytetracycline+gene+cluster+in+selected+Streptomyces+rimosus+strains+can+provide+significantly+increased+titers&rft.jtitle=Microbial+cell+factories&rft.au=Pikl%2C+%C5%A0pela&rft.au=Carrillo+Rinc%C3%B3n%2C+Andr%C3%A9s+Felipe&rft.au=Slemc%2C+Lucija&rft.au=Goranovi%C4%8D%2C+Du%C5%A1an&rft.date=2021-02-17&rft.eissn=1475-2859&rft.volume=20&rft.issue=1&rft.spage=47&rft_id=info:doi/10.1186%2Fs12934-021-01522-5&rft_id=info%3Apmid%2F33596911&rft.externalDocID=33596911 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2859&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2859&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2859&client=summon |